FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors



Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
22012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
32014029620210/02/14Substituted piperidinyl compounds useful as gpr119 agonists
42014029622110/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
52014029622210/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
62014027501709/18/14Cgrp receptor antagonists
72014025681809/11/14Nano-suspension process
82014024428908/28/14Cold storage system for storing pharmaceutical product containers
92014023429608/21/14Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
102014023430108/21/14Modulation of pilr to treat immune disorders
112014023553708/21/14N-glycosylated insulin analogues
122014022562708/14/14Device for calibrating and verifying the integrity of resistivity-based sensing probes
132014022722308/14/14Pegylated interleukin-10
142014022725008/14/14Stable formulations of antibodies to tslp
152014022729008/14/14Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
162014022729208/14/14Anti-mcam antibodies and associated methods of use
172014022002708/07/141d05 pcsk9 antagonists
182014022138308/07/14Cetp inhibitors
192014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
202014020656307/24/14Biomarkers for psoriasis
212014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
222014020664107/24/14Remedy
232014020666507/24/14Selective glycosidase inhibitors and uses thereof
242014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
252014020671507/24/14Preparation and use of compounds as protease inhibitors
262014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
272014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
282014017015406/19/14Engineered anti-il-23r antibodies
292014017065806/19/14Mammalian cytokines; related reagents
302014017143706/19/14Oxazole derivatives useful as inhibitors of faah
312014017145606/19/14Fused tricyclic compounds as mtor inhibitors
322014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
332014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
342014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
352014014744205/29/14Use of il-23 antagonists for treatment of infection
362014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
372014014095405/22/14Methods of modulating cytokine activity; related reagents
382014014101205/22/14Engineered anti-tslp antibody
392014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
402014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
412014014211505/22/14Inhibitors of the renal outer medullary potassium channel
422014014095405/22/14Methods of modulating cytokine activity; related reagents
432014014101205/22/14Engineered anti-tslp antibody
442014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
452014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
462014014211505/22/14Inhibitors of the renal outer medullary potassium channel
472014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
482014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
492014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
502014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
512014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
522014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
532014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
542014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
552014011291904/24/14Interleukin-10 antibodies
562014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
572014011291904/24/14Interleukin-10 antibodies
582014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
592014010588704/17/14Methods for modulating il-33 activity
602014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
612014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
622014010588704/17/14Methods for modulating il-33 activity
632014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
642014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
652014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
662014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
672014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
682014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
692014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
702014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
712014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
722014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
732014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
742014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
752014004574602/13/14Antidiabetic tricyclic compounds
762014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
772014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
782014003762702/06/14Modulation of pilr receptors to treat microbial infections
792014003894202/06/14Rorgammat inhibitors
802014003897002/06/14Bridged and fused antidiabetic compounds
812014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
822014003076001/30/14Pavec
832014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
842014003134901/30/14Inhibitors of the renal outer medullary potassium channel
852014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
862014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
872013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
882013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
892013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
902013032323912/05/13Modulation of pilr receptors to treat sepsis
912013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
922013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
932013032448312/05/13Mammalian cell surface antigens; related reagents
942013032461012/05/13Cathepsin cysteine protease inhibitors
952013032472812/05/13Process for the preparation of an orexin receptor antagonist
962013031635411/28/13Mammalian cytokine; related reagents
972013029627811/07/13Diazeniumdiolate derivatives
982013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
992013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
1002013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
1012013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1022013025167709/26/13Genetic markers associated with interferon-alpha response
1032013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
1042013023751809/12/13Novel compounds that are erk inhibitors
1052013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
1062013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1072013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1082013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1092013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1102013021657508/22/13Recombinant subunit dengue virus vaccine
1112013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1122013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1132013021776608/22/13Formulations for cathepsin k inhibitors
1142013021657508/22/13Recombinant subunit dengue virus vaccine
1152013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1162013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1172013021776608/22/13Formulations for cathepsin k inhibitors
1182013020306008/08/13Mammalian genes; related reagents
1192013020306008/08/13Mammalian genes; related reagents
1202013018927807/25/13Antagonists of pcsk9
1212013018927807/25/13Antagonists of pcsk9
1222013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1232013015672906/20/13Mammalian receptor proteins; related reagents and methods
1242013015677106/20/13Fdf03 antibodies and uses thereof
1252013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1262013015672906/20/13Mammalian receptor proteins; related reagents and methods
1272013015677106/20/13Fdf03 antibodies and uses thereof
1282013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1292013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1302013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1312013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1322013013104105/23/13Spirocyclic compounds
1332013013104205/23/13Spiroxazolidinone compounds
1342013013104105/23/13Spirocyclic compounds
1352013013104205/23/13Spiroxazolidinone compounds
1362013012200905/16/13Engineered anti-il-23p19 antibodies
1372013012320005/16/13Mammalian cell surface antigens; related reagents
1382013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1392013012200905/16/13Engineered anti-il-23p19 antibodies
1402013012320005/16/13Mammalian cell surface antigens; related reagents
1412013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1422013011522305/09/13Antagonists of pcsk9
1432013011623105/09/13Tyrosine kinase inhibitors
1442013011522305/09/13Antagonists of pcsk9
1452013011623105/09/13Tyrosine kinase inhibitors
1462013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1472013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1482013007139003/21/13Method for preparing antibodies having improved properties
1492013006481703/14/13Engineered anti-il-23r antibodies
1502013005985003/07/13Aza-indole derivatives useful as modulators of faah
1512013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1522013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1532013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1542013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1552013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1562013003531202/07/13Cathepsin cysteine protease inhibiors
1572013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1582013001804801/17/13Oxazole derivatives useful as modulators of faah
1592013001252601/10/13Oxazole derivatives useful as modulators of faah
1602013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1612013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1622012032967912/27/12Eukaryotic cell display systems
1632012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1642012031620012/13/12Pyridone derivatives
1652012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1662012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1672012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1682012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1692012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1702012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1712012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1722012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1732012019690108/02/12Tertiary amide orexin receptor antagonists
1742012019070107/26/12Renin inhibitors
1752012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
1762012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
1772012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1782012016415806/28/12Anti-addl monoclonal antibody and use thereof
1792012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1802012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1812012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
1822012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
1832012014275206/07/12Hiv protease inhibitors
1842012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
1852012012162405/17/12Hepatitis c virus ns3 protease inhibitors
1862012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
1872012012150805/17/12Radiolabeled cgrp antagonists
1882012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
1892012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1902012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1912012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1922012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
1932012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
1942012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
1952012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
1962012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1972012008348304/05/12Inhibitors of hepatitis c virus replication
1982012008267904/05/12Antagonists of pcsk9
1992012008268004/05/12Antagonists of pcsk9
2002012007679903/29/12Antagonists of pcsk9
2012012007796403/29/12Antagonists of pcsk9
2022012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
2032012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
2042012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
2052012003521402/09/12Renin inhibitors
2062012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
2072012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
2082012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
2092012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
2102012002107401/26/12P2x3, receptor antagonists for treatment of pain
2112012002194801/26/12Surface display of whole antibodies in eukaryotes
2122012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
2132012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
2142012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
2152012000958001/12/12Methods for quantitating small rna molecules
2162012001019301/12/12Cgrp receptor antagonists
2172012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
2182012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
2192012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
2202012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
2212011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2222011030107912/08/11Neuromedin u receptor agonists and uses thereof
2232011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules
2242011029473512/01/11Mechanism of neuromedin u action and uses thereof
2252011029477712/01/11Beta-lactamase inhibitors
2262011026353310/27/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2272011025059110/13/11Method of designing sirnas for gene silencing
2282011025120710/13/11Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
2292011024051110/06/11Packaging for oxygen-sensitive pharmaceutical products
2302011023763409/29/11Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
2312011022950809/22/11Polypeptides for inducing a protective immune response against staphylococcus aureus
2322011023049809/22/11Biaryl carboxamides
2332011023052609/22/11Thiazolyl mglur5 antagonists and methods for their use
2342011022419309/15/11Inhibitors of diacylglycerol acyltransferase
2352011022413409/15/11Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
2362011022419509/15/11Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
2372011021817409/08/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2382011021820209/08/11Soluble guanylate cyclase activators
2392011020773708/25/11Substituted bicyclic amines for the treatment of diabetes
2402011020794208/25/11Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]-oxepino[4,5-c]pyrrole
2412011020162108/18/11Angiotensin ii receptor antagonists
2422011019595708/11/11Substituted diazepan orexin receptor antagonists
2432011019030808/04/11Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
2442011019034608/04/11Diphenyl substituted alkanes as flap inhibitors
2452011017805907/21/111,3-oxazolidin -2-one derivatives useful as cetp inhibitors
2462011017811707/21/11Oxazolobenzimidazole derivatives
2472011017881907/21/11Devices and methods for determining a patient's propensity to adhere to a medication prescription
2482011017220507/14/11Monocyclic amide cgrp receptor antagonists
2492011015230406/23/11Spiroazaindoles


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo